胃癌治疗与免疫调节因子研究近况

被引：7

作者：

朱金水

王冠庭

徐家裕

机构：

[1] 上海第二医科大学附属瑞金医院,上海第二医科大学附属瑞金医院,上海第二医科大学附属瑞金医院,

来源：

国外医学(内科学分册) | 1992年 / 06期

关键词：

γ-IFN,γ-interferonγ-干扰素; IL-2,intcrleukin-2白介素-2; IL-2R,interleukin-2 receptor白介素-2受体; SIL-2R,soluble interleukin-2 receptor可溶性自介素-2受体; TNF,tumor necrosis factor肿瘤坏死因子;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

胃癌病人白介素-2受体和白介素-2均降低,且随病程进展而进行性下降,并与治疗密切相关.肿瘤坏死因子水平在术前升高,术后下降.可溶性白介素-2受体在实体瘤中显著升高,与国际癌症分类法分期相关.目前认为,监测上述免疫调节因子为胃癌免疫治疗疗效考核、预后判断提供了新的检测指标.

引用

页码：249 / 251

页数：3

共 4 条

[1]

SOLUBLE INTERLEUKIN-2 RECEPTOR AND SOLUBLE CD8 ANTIGEN LEVELS IN SERUM FROM PATIENTS WITH NONRESECTABLE LUNG-CANCER [J].

VIBEPETERSEN, J ;

TVEDE, N ;

DIAMANT, M ;

KJERULFF, AA ;

SORENSEN, HR ;

ANDERSEN, V .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 1991, 33 (02) :121-127

[2]

Serum soluble interleukin-2 (IL-2) receptor levels in women with breast carcinoma and its correlation with IL-2 receptor expression on blood lymphocytes and lymphocytic infiltration within the tumour.[J].Sadhna Sharma;K. Saha;R. N. Shinghal;Gauri Bazaz Malik.Cancer Immunology Immunotherapy.1991, 3

[3]

Induction of lymphokine-activated killer cytotoxicity with interleukin-2 and tumor necrosis factor-α against primary lung cancer targets.[J].Stephen C. Yang;Laurie Owen-Schaub;Elizabeth A. Grimm;Jack A. Roth.Cancer Immunology; Immunotherapy.1989, 3

[4]

INCREASED PRODUCTION OF TUMOR-NECROSIS-FACTOR AND PROSTAGLANDIN-E2 BY MONOCYTES IN CANCER-PATIENTS AND ITS UNIQUE MODULATION BY THEIR PLASMA [J].

NARA, K ;

ODAGIRI, H ;

FUJII, M ;

YAMANAKA, Y ;

YOKOYAMA, M ;

MORITA, T ;

SASAKI, M ;

KON, M ;

ABO, T .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 1987, 25 (02) :126-132

← 1 →